Adaptive Biotechnologies Corp (ADPT)

Adaptive Biotechnologies is a biotech company that built a platform to decode the adaptive immune system—the part of your body that remembers and fights off threats. Instead of looking at the disease directly, it reads the immune system’s response, which is like finding a fingerprint of what’s going on inside you.

The company’s main product is clonoSEQ, a clinical diagnostic test that detects and tracks minimal residual disease (MRD)—the tiny number of cancer cells left after treatment. For cancer patients in remission, knowing whether those cells are still lurking matters more than any other single fact. Oncologists use it to spot relapse risk before imaging or blood work would catch it. It’s become standard-of-care testing in certain cancers, and that’s the wedge Adaptive is using to grow.

Beyond diagnostics, the company licenses its immunosequencing tech to pharma partners developing new therapies. It has a partnership with Genentech to create neoantigen-directed T cell treatments—the kind of personalized cancer therapy that sounds science-fiction but is becoming routine. The idea is to teach a patient’s immune cells to recognize and kill cancer cells with specific mutations. Adaptive’s platform finds which immune cells are already fighting the cancer, helps design new ones, and then tracks whether the therapy is working.

The business model mixes recurring diagnostic revenue (clonoSEQ), contract research and development fees, and upfront or milestone payments from pharma partners. The diagnostic side is the most predictable and highest-margin revenue stream. The partnership revenue is lumpier but has enormous upside if Genentech or other partners get therapies through the FDA.

This is a company in the thick of the shift toward precision medicine—where treatments and monitoring are tailored to the patient’s biology, not just the disease label. If you’re tracking healthcare stocks or biotech, Adaptive sits at the intersection of diagnostics and therapeutics, which is where the capital and FDA attention are flowing right now.